Designing visible-light optical coherence tomography towards clinics.
Optical coherence tomography (OCT)
high resolution imaging
ophthalmology
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
10
7
2019
Statut:
ppublish
Résumé
The capabilities of visible-light optical coherence tomography (vis-OCT) in noninvasive anatomical and functional retinal imaging have been demonstrated by multiple groups in both rodents and healthy human subjects. Translating laboratory prototypes to an integrated clinical-environment-friendly system is required to explore the full potential of vis-OCT in disease management. We developed and optimized a portable vis-OCT system for human retinal imaging in clinical settings. We acquired raster- and circular-scan images from both healthy and diseased human eyes. The new vis-OCT provided high-quality retinal images of both subjects without any known eye diseases and patients with various retinal diseases, including retinal occlusive disease and diabetic retinopathy (DR) over a broad range of ages. A newly designed vis-OCT system is sufficiently optimized to be suited for routine patients' examinations in clinics. Vis-OCT has the potential to add new anatomical and functional imaging capabilities to ophthalmic clinical care.
Sections du résumé
BACKGROUND
BACKGROUND
The capabilities of visible-light optical coherence tomography (vis-OCT) in noninvasive anatomical and functional retinal imaging have been demonstrated by multiple groups in both rodents and healthy human subjects. Translating laboratory prototypes to an integrated clinical-environment-friendly system is required to explore the full potential of vis-OCT in disease management.
METHODS
METHODS
We developed and optimized a portable vis-OCT system for human retinal imaging in clinical settings. We acquired raster- and circular-scan images from both healthy and diseased human eyes.
RESULTS
RESULTS
The new vis-OCT provided high-quality retinal images of both subjects without any known eye diseases and patients with various retinal diseases, including retinal occlusive disease and diabetic retinopathy (DR) over a broad range of ages.
CONCLUSIONS
CONCLUSIONS
A newly designed vis-OCT system is sufficiently optimized to be suited for routine patients' examinations in clinics. Vis-OCT has the potential to add new anatomical and functional imaging capabilities to ophthalmic clinical care.
Identifiants
pubmed: 31281773
doi: 10.21037/qims.2019.05.01
pii: qims-09-05-769
pmc: PMC6571199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
769-781Subventions
Organisme : NIDDK NIH HHS
ID : DP3 DK108248
Pays : United States
Organisme : NEI NIH HHS
ID : R44 EY026466
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028304
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029121
Pays : United States
Organisme : NEI NIH HHS
ID : T32 EY025202
Pays : United States
Organisme : NEI NIH HHS
ID : R43 EY028475
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026078
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest: JS Schuman and HF Zhang have financial interests in Opticent Health. Y Wang is a full-time employee of Opticent Health. R Kuranov is a part-time employee of Opticent Health. The other authors have no conflicts of interest to declare.
Références
J Biomed Opt. 2002 Jul;7(3):359-71
pubmed: 12175285
Prog Retin Eye Res. 2005 Jul;24(4):493-519
pubmed: 15845346
JAMA. 2007 Aug 22;298(8):902-16
pubmed: 17712074
Science. 1991 Nov 22;254(5035):1178-81
pubmed: 1957169
J Cataract Refract Surg. 2010 Feb;36(2):308-12
pubmed: 20152615
Prog Retin Eye Res. 2011 Nov;30(6):431-51
pubmed: 21729763
Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):6737-42
pubmed: 21730345
Opt Express. 2011 Sep 26;19(20):19653-9
pubmed: 21996906
Nat Photonics. 2011 Dec 1;5(12):744-747
pubmed: 23144652
Exp Eye Res. 1990 Apr;50(4):393-5
pubmed: 2338122
Phys Med Biol. 2013 Jun 7;58(11):R37-61
pubmed: 23666068
Prog Retin Eye Res. 2014 Jul;41:26-43
pubmed: 24704352
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii24-9
pubmed: 24934220
Sci Rep. 2014 Oct 06;4:6525
pubmed: 25283870
Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2395-402
pubmed: 25897021
Biomed Opt Express. 2015 Mar 24;6(4):1429-50
pubmed: 25909026
IEEE Trans Biomed Eng. 2015 Sep;62(9):2308-15
pubmed: 25955984
Biomed Opt Express. 2015 Sep 01;6(10):3701-13
pubmed: 26504622
Sci Rep. 2015 Nov 18;5:16752
pubmed: 26576731
Light Sci Appl. 2015 Sep;4(9):
pubmed: 26658555
Opt Lett. 2015 Dec 15;40(24):5782-5
pubmed: 26670511
J Biomed Opt. 2016 Jun 1;21(6):66013
pubmed: 27304421
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5665-5671
pubmed: 27784071
Prog Retin Eye Res. 2017 Mar;57:76-88
pubmed: 27916682
Biomed Opt Express. 2016 Dec 19;8(1):323-337
pubmed: 28101421
Prog Retin Eye Res. 2017 May;58:115-151
pubmed: 28109737
Biomed Opt Express. 2017 Jan 12;8(2):800-812
pubmed: 28270986
J Biomed Opt. 2017 May 1;22(5):56003
pubmed: 28492851
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):981-989
pubmed: 28535269
Biomed Opt Express. 2017 Feb 07;8(3):1415-1429
pubmed: 28663838
Biomed Opt Express. 2017 May 04;8(6):2851-2865
pubmed: 28663911
Prog Retin Eye Res. 2017 Sep;60:66-100
pubmed: 28760677
Biomed Opt Express. 2017 Aug 07;8(9):4007-4025
pubmed: 28966843
J Biomed Opt. 2017 Oct;22(12):1-8
pubmed: 29043714
J Biomed Opt. 2017 Dec;22(12):1-14
pubmed: 29218923
Biomed Opt Express. 2018 Apr 04;9(5):2056-2067
pubmed: 29760969